356,528 Shares in Shattuck Labs, Inc. $STTK Acquired by Deutsche Bank AG

Deutsche Bank AG acquired a new stake in Shattuck Labs, Inc. (NASDAQ:STTK) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 356,528 shares of the company’s stock, valued at approximately $2,474,000.

Several other institutional investors have also added to or reduced their stakes in STTK. Virtu Financial LLC bought a new position in shares of Shattuck Labs during the third quarter valued at $38,000. Squarepoint Ops LLC purchased a new position in Shattuck Labs in the 3rd quarter worth about $46,000. State of Wyoming purchased a new position in Shattuck Labs in the 2nd quarter worth about $151,000. Dimensional Fund Advisors LP bought a new position in Shattuck Labs during the 4th quarter valued at about $85,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in shares of Shattuck Labs during the 4th quarter valued at about $97,000. 58.74% of the stock is currently owned by hedge funds and other institutional investors.

Shattuck Labs Trading Down 3.2%

NASDAQ STTK opened at $7.65 on Friday. Shattuck Labs, Inc. has a 12 month low of $0.97 and a 12 month high of $8.33. The stock has a market cap of $767.75 million, a price-to-earnings ratio of -15.00 and a beta of 1.08. The company’s 50 day moving average is $7.00 and its two-hundred day moving average is $6.20.

Shattuck Labs (NASDAQ:STTK) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.12). Sell-side analysts forecast that Shattuck Labs, Inc. will post -0.44 EPS for the current year.

Insider Buying and Selling at Shattuck Labs

In other news, insider Abhinav A. Shukla sold 23,365 shares of the company’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $7.08, for a total value of $165,424.20. Following the completion of the transaction, the insider owned 86,380 shares of the company’s stock, valued at $611,570.40. This represents a 21.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Clay B. Siegall bought 62,500 shares of the business’s stock in a transaction that occurred on Tuesday, June 9th. The shares were acquired at an average price of $4.00 per share, with a total value of $250,000.00. Following the transaction, the director directly owned 318,608 shares of the company’s stock, valued at $1,274,432. This represents a 24.40% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have sold a total of 53,875 shares of company stock valued at $379,305 over the last ninety days. 8.79% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

STTK has been the topic of a number of research analyst reports. Weiss Ratings upgraded shares of Shattuck Labs from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, June 16th. Raymond James Financial initiated coverage on Shattuck Labs in a report on Monday. They set a “strong-buy” rating and a $18.00 price target on the stock. HC Wainwright dropped their price target on Shattuck Labs from $18.00 to $14.00 and set a “buy” rating on the stock in a research note on Tuesday, August 11th. TD Cowen upgraded Shattuck Labs to a “strong-buy” rating in a research report on Monday. Finally, Wedbush increased their target price on Shattuck Labs from $8.00 to $11.00 and gave the company an “outperform” rating in a report on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $12.78.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical?stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten?carrier conjugate technology designed to generate high?affinity drug?specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood?brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.